COVID-19 Vaccine | SAHPRA approves the use of Sinovac vaccine

The South African Health Products Regulatory Authority has approved the use of the Sinovac Covid-19 vaccine. However, under certain conditions. To discuss this further, Masego Rahlaga speaks to Virologist and Clinical Research Specialist Dr Sanet Aspinall and Numolux Group Chief Operating Officer Anton Arendse. Courtesy #DStv403

JOHANNESBURG - The South African Health Products Regulatory Authority has approved the use of the Sinovac Covid-19 vaccine.

However, under certain conditions.

READ: 'Decision on Sinovac will be made soon' - SAHPRA

The approval is under Section 21 of the Medicines and Related Substance Act.

Individuals between the ages of 18 and 59 years can use the vaccine.

There are two doses that are administered 14 to 28 days apart.

One of the conditions is that Sinovac must submit the final results of ongoing clinical studies.

READ: WATCH | Sinovac safety and efficacy in the spotlight

It also needs to submit periodic safety updates.

The Sinovac vaccine has a provisional shelf life of 24 months.

Source
eNCA

Paid Content